COAG Hemab Therapeutics (COAG) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0002114044
Cluster · 4 insidersActivist 13D
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
57
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · no price filed
What the filings say about COAG
Insiders, 180 days
+$55.5M net bought
4 buyers
Activist stakes (13D), 180 days
1 filing
Largest: 10.4% of the class
Hemab Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Hemab Therapeutics Holdings, Inc. insiders bought a net $55.5M of stock across 16 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jun 15, 2026.
- +98.1% median (+90.0% mean) 90-day return after 3 previous buys.
- The trade is 1.0% of the 6,444,637 shares held after it.
- No other insider bought within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RA CAPITAL MANAGEMENT, L.P. bought about $1.5M of COAG on Jun 16, 2026; 57 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on May 20, 2026.
- +104.4% median (+104.4% mean) 90-day return after 2 previous buys.
- The trade is 0.1% of the 6,383,114 shares held after it.
- No other insider bought within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RA CAPITAL MANAGEMENT, L.P. bought about $153.0K of COAG on Jun 15, 2026; 57 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 19, 2026.
- The trade is 0.0% of the 6,376,968 shares held after it.
- 3 other insiders bought within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RA CAPITAL MANAGEMENT, L.P. bought about $24.8K of COAG on May 20, 2026; 3 other insiders bought within 30 days and 57 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.1% of the 6,375,972 shares held after it.
- 3 other insiders bought within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RA CAPITAL MANAGEMENT, L.P. bought about $94.9K of COAG on May 19, 2026; 3 other insiders bought within 30 days and 57 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.1% of the 6,372,170 shares held after it.
- 3 other insiders bought within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Kolchinsky Peter bought about $159.0K of COAG on May 12, 2026; 3 other insiders bought within 30 days and 57 funds added in the latest 13F quarter.16 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$55.5M over 180 days
+$55.5M of it by a 10%+ holder
more than 98% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
57 funds bought in last quarter
more than 50% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
16.7% of the float short (float per yahoo 2026-10-26) · 4.2 days to cover · settled 2026-09-30
more than 61% of Pharma & Biotech
The situation: each line is one rule over one dataset
AI DEN-MAB LLC disclosed a 5%+ stake (10.4%) in the last six months.
What changed in the last 30 days
Oct 27Insider buying stopped: no purchases in 90 days after 16 in the prior 90
Why it matters
The absence is the signal: 16 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch COAG
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+1.2%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns COAG: institutional holders (13F)
13F holdings, latest reported quarter
7,808,627 sh
$286.8M
4,180,550 sh
$153.6M
3,697,837 sh
$135.8M
3,603,876 sh
$132.4M
3,602,093 sh
$132.3M
Congress trades in COAG
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
AI DEN-MAB LLC
Activist 13D · 2026-05-11
10.4%
Access Industries Holdings LLC
Activist 13D · 2026-05-11
10.4%
AI Biotechnology LLC
Activist 13D · 2026-05-11
10.4%
Access Industries Management LLC
Activist 13D · 2026-05-11
10.4%
Len Blavatnik
Activist 13D · 2026-05-11
10.4%
COAG planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
COAG mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
JPMorgan Small Cap Growth Fund
$19.5M position · as of 2026-06-30
0.7%
Driehaus Micro Cap Growth Fund
$2.8M position · as of 2026-06-30
0.5%
Fidelity Advisor Biotechnology Fund
$8.9M position · as of 2026-07-31
0.4%
JPMorgan Small Cap Blend Fund
$6.3M position · as of 2026-06-30
0.4%
Fidelity Stock Selector Small Cap Fund
$20.9M position · as of 2026-07-31
0.3%
Fidelity Series Small Cap Opportunities Fund
$12.7M position · as of 2026-07-31
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $55.5M bought by insiders over 180 days, 57 funds added last quarter. Each figure is a federal filing, dated the day it went public.
COAG Stock Sonar score 3/7 axes
Find similar shapesCompareCOAG ranks highest on insider conviction (96th percentile) and institutional and government (50th), and lowest on risk and compliance (22nd), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
COAG filings, in plain words
Are Hemab Therapeutics insiders buying or selling COAG?
In the 180 days to 2026-10-27, Hemab Therapeutics insiders were net buyers, a net $55.5M across purchases and sales reported on Form 4, by 4 buyers.
Read the full summary
In the 180 days to 2026-10-27, Hemab Therapeutics insiders were net buyers of COAG, a net $55.5M across purchases and sales reported on Form 4 by 4 buyers. Most of that figure, $55.5M, came from a holder of 10% or more rather than an officer or director. 4 insiders reported purchases in that window. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 10.4% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
